Humana Inc. (NYSE:HUM) to Post Q1 2024 Earnings of $6.07 Per Share, Zacks Research Forecasts

Humana Inc. (NYSE:HUMFree Report) – Analysts at Zacks Research dropped their Q1 2024 earnings estimates for Humana in a report issued on Thursday, February 8th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will earn $6.07 per share for the quarter, down from their prior forecast of $10.48. The consensus estimate for Humana’s current full-year earnings is $16.03 per share. Zacks Research also issued estimates for Humana’s Q2 2024 earnings at $5.58 EPS, Q3 2024 earnings at $4.23 EPS, Q4 2024 earnings at $0.14 EPS, FY2024 earnings at $16.02 EPS, Q1 2025 earnings at $6.16 EPS, Q2 2025 earnings at $6.20 EPS, Q3 2025 earnings at $5.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $22.32 EPS.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The firm’s revenue was up 17.9% on a year-over-year basis.

A number of other analysts have also recently issued reports on HUM. Argus raised shares of Humana from a “hold” rating to a “buy” rating and set a $550.00 price objective for the company in a research note on Tuesday, December 12th. The Goldman Sachs Group cut their target price on shares of Humana from $515.00 to $450.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Truist Financial reaffirmed a “hold” rating and set a $550.00 target price on shares of Humana in a research note on Friday, January 19th. TheStreet cut shares of Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $595.00 to $360.00 in a research note on Thursday, January 25th. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $506.72.

Read Our Latest Analysis on HUM

Humana Stock Performance

Shares of NYSE HUM opened at $369.14 on Monday. The firm has a fifty day moving average price of $432.41 and a 200-day moving average price of $470.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.37. The stock has a market cap of $45.44 billion, a PE ratio of 18.62, a price-to-earnings-growth ratio of 2.17 and a beta of 0.46. Humana has a 1 year low of $342.69 and a 1 year high of $541.21.

Institutional Trading of Humana

A number of hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in Humana by 2.5% during the second quarter. State Street Corp now owns 5,852,050 shares of the insurance provider’s stock worth $2,621,731,000 after buying an additional 143,883 shares in the last quarter. Capital World Investors lifted its holdings in Humana by 18.7% during the second quarter. Capital World Investors now owns 2,322,684 shares of the insurance provider’s stock valued at $1,038,513,000 after purchasing an additional 366,007 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Humana by 2.6% during the second quarter. Geode Capital Management LLC now owns 2,293,170 shares of the insurance provider’s stock valued at $1,022,332,000 after purchasing an additional 58,693 shares in the last quarter. Morgan Stanley grew its position in shares of Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after purchasing an additional 119,760 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in shares of Humana by 35.9% in the third quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares in the last quarter. 91.86% of the stock is owned by hedge funds and other institutional investors.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.